Navigation Links
BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
Date:9/24/2008

REHOVOT, Israel, September 24 /PRNewswire-FirstCall/ -- BioView Ltd, (TASE: BIOV) from Rehovot, Israel, reported today results of its internal clinical trial of the non-invasive diagnostic test under development for early detection of lung cancer.

In the trial a total of 76 sputum samples were collected from four groups of patients:

1. Healthy individuals that never smoked

2. Heavy smokers with no signs of lung cancer

3. Early stage lung cancer patients (Stage 1)

4. Advanced stage lung cancer patients

The sputum samples were blindly scanned and analyzed morphologically and genetically, with fluorescent probes exclusively licensed to BioView, on BioView's automated Duet scanning station by Company personnel. The results of the test were classified as "Normal", i.e. no cancer detected and "Abnormal", i.e. Cancer detected. These results were then compared to the actual data received from the hospital of the patients' condition.

The samples included 32 cases of lung cancer patients (about half of them early stage patients) and 44 samples taken from people with no clinical evidence of lung cancer. Thirty one of the thirty two (96.9%) sick patients were correctly diagnosed as "Abnormal" and thirty six of forty four (about 82%) healthy people were correctly diagnosed as "Normal".

Project leader, Dr. Michal Daniely says:"We have gained great confidence in this test as we see a direct relationship between our results and the clinical status of the patients".

Dr. Opher Shapira, BioView's CEO commented: "We are extremely pleased with the results; the specificity and sensitivity in this test are better than other non-invasive tests presently available for early lung cancer detection. We are accelerating our development efforts to improve these results as well as to increase our sample size and to include other laboratories in the clinical trials."

BioView lung cancer test in based on morphological and genetic analysis of sputum samples and it is running on BioView DUETTM automated scanning platform.

About BioView Ltd.

Established in 2000, and led by an expert team of biologists, software engineers and physicists, BioView develops, manufactures and supplies cell imaging equipment, biological kits and software to medical institutes and universities. BioView is a publicly traded company on the Israeli Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions. For more information about the BioView technology, and press related issues, please contact info@bioview.co.il or visit our website at http://www.bioview.co.il.

Dr. Opher Shapira

President and CEO

Tel: +972-8-936-6868

Fax: +972-8-936-6869

e-mail: opher@bioview.co.il


'/>"/>
SOURCE BioView Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
2. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
3. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
4. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
5. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
6. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
7. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
8. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
9. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
10. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
11. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/7/2017)... 6, 2017   Provista, a proven leader ... billion in purchasing power, today announced a new resource ... The Newsroom is the online home for case ... expert bios, news releases, slideshows and events. ... wealth of resources at their fingertips, viewers can also ...
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):